|Title:||Glycosylation increases the anti-QS as well as anti-biofilm and anti-adhesion ability of the cyclo (L-Trp-L-Ser) against Pseudomonas aeruginosa||Authors:||Wang, Yinglu
|Keywords:||Quorum sensing inhibitor;Pseudomonas aeruginosa;Glycosylation;Biofilm;Drug combination||Issue Date:||5-Aug-2022||Publisher:||ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER||Journal Volume:||238||Source:||EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY||Abstract:||
Pseudomonas aeruginosa infections pose a huge threat to cystic fibrosis patients, as well as those suffering from immunodeficiency. Antimicrobial resistance, especially multi-drug resistance, due to its ability to aggregate the compact biofilm, makes it more inefficient to treat this pathogen with traditional antibiotics. Biofilm and quorum sensing (QS) have become the alternative targets for treating P. aeruginosa infections. Previously, a cyclic dipeptide cyclo(L-Trp-L-Ser) has been identified as a QS inhibitor of P. aeruginosa. On the other hand, some monosaccharides have been proved lectin-targeting behavior and to mediate biofilm formation and adhesion of P. aeruginosa. We constructed novel cyclic dipeptide-carbohydrate conjugates as a low molecular weight dualfunctional QS inhibitor, which can not only enhance its anti-QS activity but also enable good anti-biofilm and anti-adhesion ability. The IC50 of galactosylated c(WS) on biofilm formation and glass adhesion was 1/6 and 1/4 of that of the unmodified cyclic dipeptide, respectively. And the ability to eliminate the preformed biofilm was increased 10-fold. Furthermore, the carbohydrate conjugates can increase the germicidal efficiency of clinical antibiotic azithromycin when used synergistically. Our results provide a novel scaffold for developing antivirulence adjuvants when taken with clinical antibiotics.
|Appears in Collections:||食品科學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.